Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biametrics Launches b-screen® Microarray Screening Device

Published: Wednesday, March 19, 2014
Last Updated: Wednesday, March 19, 2014
Bookmark and Share
Company develops b-portable® for early cancer and infection detection.

Biametrics GmbH has announced the launch of its b-screen® label-free microarray screening device in European markets.

The device is an analysis tool for microarrays in the standard microscope format allowing the detailed studies of biomolecular interactions.

Current applications include bioanalytics, drug discovery, production and quality control. Based on the same technology, the company develops b-portable®, a point-of-care device for early cancer and infection detection.

b-screen® is able to handle different sample types like body fluids (e.g. serum or whole blood) and other relevant complex matrices such as cell culture medium.

Kinetic data can be obtained for almost any kind of biomolecular interaction such as for protein/protein, peptide/protein and small molecules/protein.

b-screen® provides a label-free read-out of up to 10,000 spots per square centimeter. It utilizes a precise and automated microfluidics system for incubation of the microarray with the sample of interest.

The device can be used with multiple array layouts (highly scalable), uses glass or plastic type substrates and is compatible with almost any common microarray printer. The high-throughput analysis is characterized by a high time resolution (no scanning) at low noise of the optical readout.

No fluorescence labels are needed, which leads to assay conditions as close as possible to the in-vivo situation combined with minimal sample pre-treatment and minimized reagent consumption.

“With b-screen® users are able to easily transfer existing microarrays directly into a label-free assay format thus gaining additional information on kinetics and thermodynamics at high precision and reliability,” says Günther Proll, Managing Director of Biametrics.

Proll continued, “The device allows very low cost high-throughput screening and the applications we have established demonstrate excellent performance and outcome characteristics. We believe b-screen® provides key advantages over current options like surface plasmon resonance (SPR)”.

Biametrics will present its b-screen® system at Analytica 2014 in Munich, Germany.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!